FRI can speed up development of novel treatments for COPD and other lung diseases.

At IRDD, May 30 in New York, Dr. De Backer will discuss the clinical relevance of understanding regional lung structure and function in the development of novel treatments for lung diseases. Functional Respiratory Imaging (FRI) and Artificial Intelligence (AI) can greatly facilitate the development of novel inhaled treatments for COPD and other lung diseases through smaller and shorter clinical trials. While significant efforts are being made to curb the use of tobacco products worldwide, air pollution has now been emerging as a major cause of lung diseases. Dr. De Backer will describe how FRI and AI can tackle this issue with a particular focus on wildfire exposure and how citizens and firefighters can be adequately protected.


Sorry, comments are closed for this post.